Human Rabies Vaccine Market: By Vaccine Type (Killed Rabies Vaccines, Rabies Immunoglobulins, Rabies Monoclonal Antibodies), By Route of Administration (Intra Muscular, Intra Dermal), By Product Type (Chicken Embryo Cell Vaccines, Vero Cells, Human Diploid Cell Vaccines), By Application (Pre-exposure Prophylaxis(Pr-EP), Post-exposure Prophylaxis (PEP)) and Geography

Human Rabies Vaccine Market size was valued at USD 1,343.6 million in 2023 and is estimated to grow at 4.9% CAGR from 2024 to 2030. Human Rabies vaccine is the class of vaccines that gives protection from a zoonotic disease called rabies mainly spread by dogs. There are three types of vaccines specifically chicken embryo cell vaccines (CCEEV), Vero cells, and Human diploid cell vaccines. The market of Human Rabies Vaccine includes killed rabies vaccines, rabies immunoglobulins, and monoclonal antibodies and recent trends are of DNA and mRNA vaccines. The key drivers of the Human Rabies Vaccine are the urbanization of stray dogs, government and various healthcare organizations initiatives, increased pet ownership, and increasing awareness about vaccines.

The opportunities for the companies for the Human Rabies Vaccine Market are the increased awareness and vaccination initiatives of certain organizations such National Rabies Control Program (NRCP) from the Indian government, the Thailand Red Cross (TRC), etc. The key trends in the market are the increasing occurrence of rabies, and presence of key players in vaccine manufacturing, and the availability of vaccines in rural areas. As per WHO, the suggestion of switching to ID (Intra-Dermal) form IM (Intra-Muscular) based administration will help reduce the Human Rabies Vaccine usage from the current scenario of 60M vials to 20M vials per year globally (driven by China). This happens because the dosage regime is significantly reduced from 0.5 - 1 ml to 0.1 ml from IM to ID respectively. The Human Rabies Vaccine market is also affected by the WHO program of increasing oral vaccination of wild and tame animals. Despite the decrease in vaccine usage, because of the “ZERO by 30” program from WHO the global Human Rabies Vaccine Market is expected to expand. The major producers and end users of the Human Rabies Vaccine in the global market are China and India.

Human Rabies Vaccine Market Key Developments:

• In April 2024. Sanofi has announced the launch of Verorab® (Sanofi Inactivated Rabies Vaccine) in the UK, an inactivated rabies vaccine indicated for pre-exposure and post-exposure rabies prophylaxis in all age groups.
• In July 2024, Gavi, the Vaccine Alliance, in collaboration with partners, is announcing support for human rabies vaccines for post-exposure prophylaxis (PEP) as part of routine immunization. Eligible countries are receiving guidance on how to access these vaccines under Gavi's cofinancing policy. The first round of applications will be accepted by mid-July 2024